Cardlytics Inc (NASDAQ:CDLX) CEO Sells $8,075,000.00 in Stock

Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes sold 250,000 shares of Cardlytics stock in a transaction on Friday, September 13th. The stock was sold at an average price of $32.30, for a total value of $8,075,000.00.

Shares of Cardlytics stock opened at $34.10 on Thursday. The stock’s 50-day simple moving average is $33.69 and its 200-day simple moving average is $24.16. Cardlytics Inc has a 52 week low of $9.80 and a 52 week high of $39.62. The company has a market capitalization of $808.56 million, a price-to-earnings ratio of -15.93 and a beta of 1.53. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.79.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. The business had revenue of $48.73 million for the quarter, compared to the consensus estimate of $43.77 million. During the same period in the previous year, the business earned ($0.21) earnings per share. The business’s revenue was up 37.0% on a year-over-year basis. On average, equities analysts expect that Cardlytics Inc will post -1.08 earnings per share for the current year.



Several equities analysts recently weighed in on CDLX shares. SunTrust Banks lifted their target price on Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Bank of America reiterated a “buy” rating and set a $32.00 target price (up from $22.00) on shares of Cardlytics in a research report on Wednesday, July 24th. Raymond James lifted their target price on Cardlytics from $24.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. set a $43.00 target price on Cardlytics and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, ValuEngine downgraded Cardlytics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $33.29.

Institutional investors have recently made changes to their positions in the company. Bank of Montreal Can lifted its position in shares of Cardlytics by 16,371.4% in the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after acquiring an additional 1,146 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in shares of Cardlytics in the second quarter worth about $60,000. Rockefeller Capital Management L.P. purchased a new stake in shares of Cardlytics in the second quarter worth about $85,000. Acadian Asset Management LLC purchased a new stake in shares of Cardlytics in the second quarter worth about $161,000. Finally, Royal Bank of Canada lifted its position in shares of Cardlytics by 166.5% in the second quarter. Royal Bank of Canada now owns 10,643 shares of the company’s stock worth $276,000 after buying an additional 6,649 shares in the last quarter. Institutional investors and hedge funds own 85.01% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Article: Marijuana Stocks

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.